UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 30, 2018
ARTELO BIOSCIENCES, INC. |
(Exact name of registrant as specified in its charter) |
Nevada |
| 333-199213 |
| 33-1220924 |
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
88 Prospect Street, Suite 210, La Jolla, CA USA |
| 92037 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code 760-943-1689
_____________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
A copy of a slide presentation that Artelo Biosciences, Inc. (the “Company”) intends to present to investors is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure.
The information referenced under Item 7.01 (including Exhibit 99.1 referenced in Item 9.01 below) of this Current Report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report. This Current Report shall not be deemed an admission as to the materiality of any information in the Current Report that is required to be disclosed solely by Regulation FD.
Item 8.01. Other Events.
On May 30, 2018, the Company issued a press release announcing that the Company’s common stock began trading on the OTCQB Market, which is operated by OTC Markets Group Inc., on May 21, 2018 under its current trading symbol “ARTL.” A copy of the press release is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
| Description |
| ||
|
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARTELO BIOSCIENCES, INC. | |
| |
/s/ Gregory Gorgas |
|
Gregory Gorgas |
|
President & CEO | |
| |
Date May 30, 2018 |
3 |
EXHIBIT 99.1
EXHIBIT 99.2
ARTELO BIOSCIENCES COMMENCES TRADING ON OTCQB
LA JOLLA, CA - May 30, 2018 - Artelo Biosciences, Inc. (OTCQB: ARTL), a biopharmaceutical company focused on the development of therapeutic treatments that modulate the endocannabinoid system, is pleased to announce that as of May 21, 2018, its shares began trading on the OTCQB under the symbol ARTL.
“The trading of Artelo’s shares on the OTCQB represents a significant strategic milestone that will help to enhance our visibility among the investor public,” said Gregory D. Gorgas, chief executive officer of Artelo Biosciences. “We look forward to sharing additional milestones in the coming months.”
The OTCQB Venture Market offers early stage and developing companies the benefits of being publicly traded in the U.S. and streamlined market standards which enable listed companies to provide a strong baseline of transparency to inform and engage with U.S. investors. To be eligible, companies must be current in their reporting, meet a minimum bid price test and undergo an annual verification and management certification process. As a verified market with efficient access to U.S. investors, OTCQB helps companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation.
About Artelo Biosciences
Artelo Biosciences, Inc. (OTCQB: ARTL) is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking Statements:
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact: ir@artelobio.com
###
2V-K$T$)0(I()8@DY)(&1TQQ1:>'KRVN;B]\^P6>6W\@116>V(?-GD;N<]
M#]?:N@DO;6*01R7$:.3M"LX!)XX_4?G3EN[9VE5;B)FB_P!8 X.SZ^E '++X
M1/V2823V\=P]PMS&L-N!!&RKMQL)Y!!.>GZ5:;0KJ6SB4RV5O?07(N(GM;7;
M&"!C#+G)R"> @7EJ][<+/8_:+N.-?*6TQ"NTG(V[LD$'&?QIL?
MA6>'3%CANH8[I+X7R!(2(5<#&P+G(7\:U!KEE-<7MK!+&]Q;#)0R*H<[=V <
M]NY[5GW.OS2:E:Z?:BSCN)H1-+]HFRJY( 0;?O,<_E0 ^]T6]U#4+2>YGL@M
MN\
MP&*GU73HM5L)+.8NL
6">X.__P =J32#=Z?:>'9(KNYG6[MG#VSL"GRQ%E"C''( H [VBN#\
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MEC(^6)W9@S8]NOX5 9] _O0!U9BC\T2F-/, P'VC('UJ3:/08SGI6#9ZX=2U&SALU1H)+3
M[5.Y.2@;A%'OG=G/I5>[UW43-J+Z?;6TEMIQQ,9G8-(P736A10!EVFDVEII]G9",21VFTQ&0 D,/XOKR>?>K,-O#;[_ "8D3S',C[5Q
MN8]2?G644<$,=I$L=NVZ%0@Q&>>1Z'D_G27.D:=>3QW
M%U8P331_==XP2*T** ,&QT^].IWU[J(MB)XDA2*$EAL4L?FW
F<$G/.?PH ZV
MH%CC3<415WG+8&,GU-
9;Y&C1Q&
MSJI8;B"0.!SP#2KJD$KV)M;JV:&[=E!).6PI.%QW!'.<=^] %;_A'@XF:\O;
MFYEEMWM5DDV@QQL.<8&-WJ3UQ5Q-&CCN["X$DFZQ@:",9&&!"C)XZ_+1;ZUI
MMW<2PPW<;O$&9P,X 4X)ST(%.T_6;#4G=+.[29D )"Y!P>_/4>XH @O=%-Q>
M/=V]YVO+F*2TG>>&<[68,Q.X$$8(^8
M]J9<>%DN/M*'4+Q+:YE$\L";,-(,?-G;GG:#CIFM*?7-+M[2.ZDO8A#/_JF!
MSO\ H!R:A&M6WVQF^U6WV-;3[23\V\#<06Z8V\?7- "Z/%>J+R:],@>:Z